TCA
BMY icon

Transcend Capital Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Transcend Capital Advisors’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.29M Sell
54,309
-2,348
-4% -$137K 0.26% 70
2025
Q4 		$3.06M Sell
56,657
-2,872
-5% -$138K 0.24% 87
2025
Q3 		$2.68M Buy
59,529
+1,953
+3% +$91.2K 0.19% 116
2025
Q2 		$2.67M Sell
57,576
-43,496
-43% -$2.14M 0.21% 115
2025
Q1 		$6.16M Sell
101,072
-94,725
-48% -$5.52M 0.44% 46
2024
Q4 		$11.1M Sell
195,797
-3,965
-2% -$222K 0.8% 24
2024
Q3 		$10.3M Sell
199,762
-1,318
-0.7% -$61.8K 0.69% 30
2024
Q2 		$8.35M Buy
201,080
+4,354
+2% +$195K 0.61% 34
2024
Q1 		$10.7M Buy
196,726
+35,159
+22% +$1.79M 0.86% 22
2023
Q4 		$8.29M Buy
161,567
+37,853
+31% +$1.99M 0.74% 26
2023
Q3 		$7.18M Sell
123,714
-1,980
-2% -$121K 0.7% 28
2023
Q2 		$8.04M Sell
125,694
-3,431
-3% -$230K 0.77% 23
2023
Q1 		$8.95M Buy
129,125
+398
+0.3% +$28.1K 0.93% 18
2022
Q4 		$9.26M Sell
128,727
-3,527
-3% -$266K 1.01% 19
2022
Q3 		$9.4M Buy
132,254
+2,893
+2% +$210K 1.04% 14
2022
Q2 		$9.96M Sell
129,361
-261
-0.2% -$19.9K 1.04% 14
2022
Q1 		$9.47M Buy
129,622
+1,349
+1% +$90.6K 0.85% 19
2021
Q4 		$8M Sell
128,273
-1,034
-0.8% -$60.7K 0.71% 24
2021
Q3 		$7.53M Sell
129,307
-32,387
-20% -$2.13M 0.68% 26
2021
Q2 		$10.8M Buy
161,694
+910
+0.6% +$59.3K 1.55% 8
2021
Q1 		$10.1M Sell
160,784
-3,213
-2% -$200K 1.22% 11
2020
Q4 		$10.2M Sell
163,997
-26,843
-14% -$1.65M 1.34% 10
2020
Q3 		$11.5M Sell
190,840
-2,869
-1% -$173K 2.09% 6
2020
Q2 		$11.4M Sell
193,709
-8,237
-4% -$493K 3.71% 4
2020
Q1 		$11.3M Sell
201,946
-1,265
-0.6% -$77.3K 3.37% 3
2019
Q4 		$13M Buy
+203,211
New +$11.6M 3.51% 3

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Transcend Capital Advisors's BMY Position: Q1 2026 in Review

Transcend Capital Advisors reduced its Bristol-Myers Squibb (BMY) stake by 4.1% in Q1 2026, selling an estimated $137K and leaving 54,309 shares worth $3.29M. The position accounts for 0.26% of the portfolio, ranked #70.

Transcend Capital Advisors first reported a position in BMY in Q4 2019 and has held it in 26 quarters since. The position peaked at $13M in Q4 2019. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Transcend Capital Advisors held 54,309 shares of Bristol-Myers Squibb worth $3.29M as of Q1 2026.
  • Transcend Capital Advisors sold 2,348 Bristol-Myers Squibb shares in Q1 2026, an estimated $137K.
  • Bristol-Myers Squibb made up 0.26% of Transcend Capital Advisors's portfolio in Q1 2026, its #70 holding.
  • Transcend Capital Advisors first reported a position in Bristol-Myers Squibb in Q4 2019 and has held it in 26 quarters since.
  • Transcend Capital Advisors's Bristol-Myers Squibb position peaked at $13M in Q4 2019.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Transcend Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.